ReviewEuropean respiratory review : an official journal of the European Respiratory Society2021
Future concepts in bronchodilation for COPD: dual-
Review in European respiratory review : an official journal of the European Respiratory Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.The New England journal of medicine · 2022Trial
- VE-VCO2 Slope During Cardiopulmonary Exercise Test Predicts Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Bu-Fei Formula Ameliorates Inflammation in a Preclinical COPD-Like Model by Targeting Mitochondrial Hyperactivity to Inhibit the NLRP3 Inflammasome.International journal of chronic obstructive pulmonary disease · 2026Article
- Treatment needs in mild-to-moderate chronic obstructive pulmonary disease: evidence from longitudinal studies.Journal of thoracic disease · 2025Article
- Pulmonary rehabilitation and physical interventions.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study.International journal of chronic obstructive pulmonary disease · 2023Article
- Circadian clock-based therapeutics in chronic pulmonary diseases.Trends in pharmacological sciences · 2022Review
- Long-acting muscarinic antagonist and long-acting βTherapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with COPD are recommended to initiate maintenance therapy with a single long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.